Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001032767 | SCV001196074 | pathogenic | Hereditary diffuse gastric adenocarcinoma | 2019-02-06 | criteria provided, single submitter | clinical testing | This variant is a sub-genic deletion of the genomic region encompassing exons 14-15 of the CDH1 gene. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product. This variant has not been reported in the literature in individuals with CDH1-related conditions. This variant is expected to affect the C-terminal portion of the cytoplasmic domain of the CDH1 (E-cadherin) protein, which includes the binding domains for the PIP5K1C (phosphatidylinositol phosphate kinase, type I gamma) and CTNNB1 (beta-catenin) proteins (PMID: 22850631). Loss of these domains is expected to disrupt normal E-cadherin function. This suggests that deletion of this region of the CDH1 protein is causative of disease. Sub-genic deletion of exons 14-16 and exon 16 have been determined to be pathogenic (PMID: PMID: 19168852, Invitae). Therefore, deletions that fully encompass that region are also expected to be pathogenic. For these reasons, this variant has been classified as Pathogenic. |